XML 45 R21.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Reporting | 12 Months Ended
--- | ---
Jun. 30, 2024
Segment Reporting [Abstract] |
Segment Reporting | Note 15. Segment Reporting Description of segments and principal activities The group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. The executive management uses the measure of profit and loss to assess segment performance. Management considers the business from both a product and a geographic perspective and has identified two reportable segments: Research and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia and United States. Hyper-immune products: income and expenses directly attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world. Financial breakdown The segment information for the reportable segments for the year ended June 30, 2024 is as follows:
|  | Research and development |  |  | Hyper-immune products |  |  | Corporate |  |  | Total |
2024 |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |
Hyper-immune products revenue |  |  | - |  |  |  | 4,902,865 |  |  |  | - |  |  |  | 4,902,865 |
Cost of sales of goods |  |  | - |  |  |  | (1,566,068 | ) |  |  | - |  |  |  | (1,566,068 | )
Gross profit |  |  | - |  |  |  | 3,336,797 |  |  |  | - |  |  |  | 3,336,797 |
Other income |  |  | 3,364,439 |  |  |  | 43,760 |  |  |  | - |  |  |  | 3,408,199 |
Fair value gains/(losses)to financial assets |  |  | - |  |  |  | - |  |  |  | (557,676 | ) |  |  | (557,676 | )
Net foreign exchange gains/(losses) |  |  | - |  |  |  | - |  |  |  | (27,603 | ) |  |  | (27,603 | )
Movement in inventory provision |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
General and administrative expenses |  |  | (460,251 | ) |  |  | (3,565 | ) |  |  | (4,091,910 | ) |  |  | (4,555,726 | )
Research and development expenses |  |  | (5,375,461 | ) |  |  | - |  |  |  | - |  |  |  | (5,375,461 | )
Selling and marketing expenses |  |  | - |  |  |  | (2,029,648 | ) |  |  | - |  |  |  | (2,029,648 | )
Operating profit/(loss) |  |  | (2,471,273 | ) |  |  | 1,347,344 |  |  |  | (4,667,184 | ) |  |  | (5,801,118 | )
Finance income |  |  | - |  |  |  | - |  |  |  | 327,756 |  |  |  | 327,756 |
Finance costs |  |  | - |  |  |  | - |  |  |  | (7,576 | ) |  |  | (7,576 | )
Share of loss from associates |  |  | - |  |  |  | - |  |  |  | (1,456,019 | ) |  |  | (1,456,019 | )
Income tax expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Profit/(loss) for the year |  |  | (2,471,273 | ) |  |  | 1,347,344 |  |  |  | (5,813,028 | ) |  |  | (6,936,957 | )
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment assets |  |  | 768,370 |  |  |  | 2,845,096 |  |  |  | 11,936,503 |  |  |  | 15,549,969 |
Total assets |  |  | 768,370 |  |  |  | 2,845,096 |  |  |  | 11,936,503 |  |  |  | 15,549,969 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment liabilities |  |  | 604,018 |  |  |  | 206,524 |  |  |  | 2,029,983 |  |  |  | 2,840,525 |
Total liabilities |  |  | 604,018 |  |  |  | 206,524 |  |  |  | 2,029,983 |  |  |  | 2,840,525 |
The segment information for the reportable segments for the year ended June 30, 2023 is as follows:
|  | Research and development |  |  | Hyper-immune products |  |  | Corporate |  |  | Total |
2023 |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |
Hyper-immune products revenue |  |  | - |  |  |  | 1,804,705 |  |  |  | - |  |  |  | 1,804,705 |
Cost of sales of goods |  |  | - |  |  |  | (495,558 | ) |  |  | - |  |  |  | (495,558 | )
Gross profit |  |  | - |  |  |  | 1,309,147 |  |  |  | - |  |  |  | 1,309,147 |
Other income |  |  | 2,551,813 |  |  |  | 39,685 |  |  |  | - |  |  |  | 2,591,498 |
Fair value gains/(losses)to financial assets |  |  | - |  |  |  | - |  |  |  | (523,666 | ) |  |  | (523,666 | )
Net foreign exchange gains/(losses) |  |  | - |  |  |  | - |  |  |  | 363,724 |  |  |  | 363,724 |
Movement in inventory provision |  |  | - |  |  |  | 430,932 |  |  |  | - |  |  |  | 430,932 |
General and administrative expenses |  |  | (460,251 | ) |  |  | 26,256 |  |  |  | (3,786,910 | ) |  |  | (4,220,905 | )
Research and development expenses |  |  | (2,592,145 | ) |  |  | - |  |  |  | - |  |  |  | (2,592,145 | )
Selling and marketing expenses |  |  | - |  |  |  | (927,423 | ) |  |  | - |  |  |  | (927,423 | )
Operating profit/(loss) |  |  | (500,583 | ) |  |  | 878,597 |  |  |  | (3,946,852 | ) |  |  | (3,568,838 | )
Finance income |  |  | - |  |  |  | - |  |  |  | 116,323 |  |  |  | 116,323 |
Finance costs |  |  | - |  |  |  | - |  |  |  | (9,652 | ) |  |  | (9,652 | )
Share of loss from associates |  |  | - |  |  |  | - |  |  |  | (324,340 | ) |  |  | (324,340 | )
Income tax expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Profit/(loss) for the year |  |  | (500,583 | ) |  |  | 878,597 |  |  |  | (4,164,521 | ) |  |  | (3,786,507 | )
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment assets |  |  | 398,391 |  |  |  | 2,078,643 |  |  |  | 19,511,148 |  |  |  | 21,988,182 |
Total assets |  |  | 398,391 |  |  |  | 2,078,643 |  |  |  | 19,511,148 |  |  |  | 21,988,182 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment liabilities |  |  | 604,018 |  |  |  | 206,524 |  |  |  | 1,560,804 |  |  |  | 2,371,346 |
Total liabilities |  |  | 604,018 |  |  |  | 206,524 |  |  |  | 1,560,804 |  |  |  | 2,371,346 |
The segment information for the reportable segments for the year ended June 30, 2022 is as follows:
|  | Research and development |  |  | Hyper-immune products |  |  | Corporate |  |  | Total |
2022 |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |
Hyper-immune products revenue |  |  | - |  |  |  | 765,193 |  |  |  | - |  |  |  | 765,193 |
Cost of sales of goods |  |  | - |  |  |  | (241,691 | ) |  |  | - |  |  |  | (241,691 | )
Gross profit |  |  | - |  |  |  | 523,502 |  |  |  | - |  |  |  | 523,502 |
Other income |  |  | 933,140 |  |  |  | 24,585 |  |  |  | - |  |  |  | 957,725 |
Net foreign exchange gains/(losses) |  |  | - |  |  |  | - |  |  |  | 247,558 |  |  |  | 247,558 |
General and administrative expenses |  |  | - |  |  |  | (164,087 | ) |  |  | (3,360,301 | ) |  |  | (3,524,388 | )
Research and development expenses |  |  | (657,715 | ) |  |  | - |  |  |  | - |  |  |  | (657,715 | )
Selling and marketing expenses |  |  | - |  |  |  | (416,537 | ) |  |  | - |  |  |  | (416,537 | )
Operating profit/(loss) |  |  | 275,425 |  |  |  | (32,537 | ) |  |  | (3,112,743 | ) |  |  | (2,869,855 | )
Finance income |  |  | - |  |  |  | - |  |  |  | 21,785 |  |  |  | 21,785 |
Finance costs |  |  | - |  |  |  | - |  |  |  | (6,184 | ) |  |  | (6,184 | )
Profit/(loss) for the year |  |  | 275,425 |  |  |  | (32,537 | ) |  |  | (3,097,142 | ) |  |  | (2,854,254 | )
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment assets |  |  | 257,500 |  |  |  | 1,688,910 |  |  |  | 22,909,414 |  |  |  | 24,855,824 |
Total assets |  |  | 257,500 |  |  |  | 1,688,910 |  |  |  | 22,909,414 |  |  |  | 24,855,824 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment liabilities |  |  | 7,053 |  |  |  | 150,151 |  |  |  | 1,521,219 |  |  |  | 1,678,423 |
Total liabilities |  |  | 7,053 |  |  |  | 150,151 |  |  |  | 1,521,219 |  |  |  | 1,678,423 |
Information on geographical regions: The group derives revenue from the transfer of hyper-immune products at a point in time in the following major product lines and geographical regions:
|  | Travelan |  |  | Protectyn |  |  |  |
|  | Australia |  |  | United States |  |  | Canada |  |  | Australia |  |  | Total |
2024 |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |
Hyper-immune products revenue |  |  | 3,702,876 |  |  |  | 1,075,614 |  |  |  | 80,888 |  |  |  | 43,487 |  |  |  | 4,902,865 |
Revenue from external customers |  |  | 3,702,876 |  |  |  | 1,075,614 |  |  |  | 80,888 |  |  |  | 43,487 |  |  |  | 4,902,865 |
|  | Travelan |  |  | Protectyn |  |  |  |
|  | Australia |  |  | United States |  |  | Canada |  |  | Australia |  |  | Total |
2023 |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |
Hyper-immune products revenue |  |  | 1,100,725 |  |  |  | 642,819 |  |  |  | 1,201 |  |  |  | 59,960 |  |  |  | 1,804,705 |
Revenue from external customers |  |  | 1,100,725 |  |  |  | 642,819 |  |  |  | 1,201 |  |  |  | 59,960 |  |  |  | 1,804,705 |
|  | Travelan |  |  | Protectyn |  |  |  |
|  | Australia |  |  | United States |  |  | Canada |  |  | Australia |  |  | Total |
2022 |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |  |  | A$ |
Hyper-immune products revenue |  |  | 143,378 |  |  |  | 501,228 |  |  |  | 63,172 |  |  |  | 57,415 |  |  |  | 765,193 |
Revenue from external customers |  |  | 143,378 |  |  |  | 501,228 |  |  |  | 63,172 |  |  |  | 57,415 |  |  |  | 765,193 |
Information on major customers: During the years ended June 30, 2024, 2023 and 2022, the Company had the following major customers in the hyper-immune product segment with revenues amounting to 10 percent or more of total group revenues:
|  | 2024 A$ |  |  | 2023 A$ |  |  | 2022 A$ |
Customer A |  |  | 2,308,425 |  |  |  | 626,107 |  |  |  | 99,792 |
Customer B |  |  | 957,076 |  |  |  | - |  |  |  | - |
Customer C |  |  | 842,173 |  |  |  | 223,504 |  |  |  | 34,020 |
Customer D |  |  | 552,509 |  |  |  | 236,437 |  |  |  | - |
Customer E |  |  | - |  |  |  | 465,614 |  |  |  | 253,803 |
Customer F |  |  | - |  |  |  | - |  |  |  | 263,137 |
|  |  | 4,660,183 |  |  |  | 1,551,662 |  |  |  | 650,752 |

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration